





DOCKET NO.: 00537-111004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Shalaby et al.

Application No.: 09/807,087

Group Art Unit: Unknown

Filed:

April 9, 2001

Examiner:

Unknown

Title:

Cir.

[X]

IONIC MOLECULAR CONJUGATES OF N-ACYLATED DERIVATIVES OF POLY(2-AMINO-2-DEOXY-D-GLUCOSE) AND POLYPEPTIDES

CERTIFICATE OF MAILING

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Assistant Commissioner for Patents Washington, D.C. 20231

Sil.		
This In	nformation Disclosure Statement is submitted: under 37 CFR 1.129(a), or	
	(First/Second submission after Final Rejection)	
[X]	under 37 CFR 1.97(b), or	
	(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office merits; whichever occurs last)	.
[]	under 37 CFR 1.97(c) together with either:	¥ .*
	[] a Statement under 37 CFR 1.97(e), as checked below, or	į
	[] a \$240.00 fee under 37 CFR 1.17(p), or	
	(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	
[]	under 37 CFR 1.97(d) together with:	
	[] a Statement under 37 CFR 1.97(e), as checked below, and	
	[] a Petition under 37 CFR 1.97(d)(2), and	
	[] a \$130.00 petition fee set forth in 37 CFR 1.17(i). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)	
[]	Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filew (Filed after payment of issue fee)	rapper.

The listed references were cited in a Hungarian Search Report in a counter part Hungarian application.

Statement Under 37 CFR 1.97(e)

l I	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
[X]	Enclosed herewith is form PTO-1449, with a copy of the reference.
[]	Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).
Concis	e Explanation Requirement (non-English references):
[X]	The "concise explanation" requirement for reference(s) HU 212662 B under 37 CFR 1.98(a)(3) is satisfied by:
	[] the explanation provided on the attached sheet.
	[] the explanation provided in the Specification.
	[] submission of the enclosed International Search Report.
	[X] the enclosed is believed to be the equivalent WO 96/04927.
CHCIOSC	juested that the information disclosed herein be made of record in this application, and that the references listed on the d form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, 1302.12).
Method	of payment:
[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
[X]	No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
[X]	The Assistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.
Dated:	Respectfully submitted, BIOMEASURE, INCORPORATED By Alan F-Feeney Attorney for Applicant(s) Registration No.: 43,609 Telephone: (508) 478-0144 Facsimile: (508) 473-3531

27 Maple Street Milford, Massachusetts 01757 PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTORNEY DOCKET NO. 00537-111004

APPLICATION NO. 09/807,087

APPLICANT

Shalaby et al.

several sheets if necessary) FILING DATE GROUP April 9, 2001 Unknown U.S. PATENT DOCUMENTS EXAMATERT & INER DOCUMENT NUMBER DATE SUB-FILING DATE INI-NAME CLASS CLASS TIAL ΙF APPROPRIATE AΑ 5,665,702 09/09/97 Shalaby et al. AB AC AD ΑE AF FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE SUB-TRANSLATION COUNTRY CLASS CLASS YES AG 0 643 963 A2 & A3. 03/22/95 Europe WO 95/04752 -ΑН 02/16/95 PCT WO 96/04927 ~ 02/22/96 ΑI PCT AJ WO 96/39160 -12/12/96 PCT HU 212662 B ΑK 08/10/94 Hungary Х AL AM AN AO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Database WPI, Derwent Publications LTD., London, GB; AN 1988-ΑP 348690[49], XP-002197084 & JP 63 258579 A (Fuji Spinning Co. LTD), October 26, 1988, Abstract Song, Y. et al., "Drug Release and Antitumor Characteristics of N- $\,$ ΑQ Succinyl-chitosan-mitomycin C as an Implant", J. Controlled Release, Vol. 42, pp. 93-100 (1996), xP000620286 AR EXAMINER DATE CONSIDERED